Manuela Valente - 19 Aug 2026 Form 4 Insider Report for SOPHiA GENETICS SA (SOPH)

Reporting relationship: Chief People Officer
Issuer ticker: SOPH
Reported as of: 19 Aug 2026
Net transaction value: -$79,439
SEC form: 4
Accepted by SEC: 21 Aug 2026, 16:02:04 UTC
Prior SEC filing: 07 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Elimara Brunetto as Attorney-in-fact for Manuela Valente

Key filing fact

Manuela Valente filed Form 4 for SOPHiA GENETICS SA (SOPH) on 21 Aug 2026.

Key facts

This page summarizes Manuela Valente's Form 4 filing for SOPHiA GENETICS SA (SOPH).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Aug 2026, 16:02.

Change

Previous filing in this sequence was filed on 07 Jul 2026.
Current net transaction value: -$79,439.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002009280 Primary reporting owner

Valente Manuela

Relationship: Chief People Officer
Address: C/O SOPHIA GENETICS SA, LA PIECE 12, ROLLE, SWITZERLAND
Signature: /s/ Elimara Brunetto as Attorney-in-fact for Manuela Valente
Signature date: 21 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SOPH transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +10,000
Change %: +4.8%
Price: $3.20^*
Shares after: 220,450
Date: 19 Aug 2026
Ownership: Direct
Footnotes: F1

SOPH transaction

Ordinary Shares

Sale

Transaction value: $79,439
Shares: -10,000
Change %: -4.5%
Price: $7.94
Shares after: 210,450
Date: 19 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SOPH transaction Derivative

Share Option (Right to Buy)

Options Exercise

Transaction value
Shares: -10,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 19 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 10,000
Exercise price: $3.20
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.90 to $8.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The share options are fully vested and exercisable.

Footnote F4

Following the transaction reported on this line, the Reporting Person holds an aggregate total of 554, 276 derivative share options across all remaining grant tranches with varying exercise prices.